Teplizumab MGA-031; PRV-031|cas:876387-05-2|西域试剂

Teplizumab MGA-031; PRV-031,99.90%

产品编号：Bellancom-P99222| CAS NO：876387-05-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99222	￥3500.00	杭州北京（现货）
Bellancom-P99222	￥8750.00	杭州北京（现货）
Bellancom-P99222	￥14000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Teplizumab MGA-031; PRV-031

产品介绍

Teplizumab (MGA-031) 是一种 Fc 受体型、非结合类型的抗-人 CD3 的单克隆抗体。Teplizumab 可缓解 β 细胞的功能丧失。Teplizumab 可用于 type 1 型糖尿病的研究。

生物活性

Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes.

体外研究

Teplizumab (10 ng/mL-10 μg/mL, 5 days) induces human CD8+ T-cell proliferation.
Teplizumab (6 days) increases the expression of CD25 and intracellular CTLA4 on CD8+ cells (freshly isolated PBMCs).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	Human PBMCs
Concentration:	10 ng/mL, 100 ng/mL, 1 μg/mL, 10 μg/mL.
Incubation Time:	5 days
Result:	Induced cell proliferation (measured by incorporation of [³H]thymidine in a 5-day assay.

体内研究
(In Vivo)

Teplizumab (0.24 mg/kg, i.p.) induces migration of human CD4 T cells to the lamina propria and ablated the treatment effects of the drug on graft survival in NSG mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID IL2γc^-/- (NSG) mice (a tolergenic humanized mouse model)
Dosage:	0.24 mg/kg, 5 μg
Administration:	Intraperitoneal injection (i.p.)
Result:	Decreased CD4:CD8 ratio in the peripheral blood from 2.03 to 1.01, p < 0.05. Decreased circulating hCD4 cells in the peripheral blood. Decreased in the proportion of T cells in the bone marrow and lung. Increased in the total number of human CD45+ cells infiltrating the lamina propria of the small intestine.

体内研究

Teplizumab (0.24 mg/kg, i.p.) induces migration of human CD4 T cells to the lamina propria and ablated the treatment effects of the drug on graft survival in NSG mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID IL2γc^-/- (NSG) mice (a tolergenic humanized mouse model)
Dosage:	0.24 mg/kg, 5 μg
Administration:	Intraperitoneal injection (i.p.)
Result:	Decreased CD4:CD8 ratio in the peripheral blood from 2.03 to 1.01, p < 0.05. Decreased circulating hCD4 cells in the peripheral blood. Decreased in the proportion of T cells in the bone marrow and lung. Increased in the total number of human CD45+ cells infiltrating the lamina propria of the small intestine.

体内研究

Teplizumab (0.24 mg/kg, i.p.) induces migration of human CD4 T cells to the lamina propria and ablated the treatment effects of the drug on graft survival in NSG mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID IL2γc^-/- (NSG) mice (a tolergenic humanized mouse model)
Dosage:	0.24 mg/kg, 5 μg
Administration:	Intraperitoneal injection (i.p.)
Result:	Decreased CD4:CD8 ratio in the peripheral blood from 2.03 to 1.01, p < 0.05. Decreased circulating hCD4 cells in the peripheral blood. Decreased in the proportion of T cells in the bone marrow and lung. Increased in the total number of human CD45+ cells infiltrating the lamina propria of the small intestine.